Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BGB-21447 + BGB-43395 + Fulvestrant |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BGB-21447 | BGB 21447|BGB21447 | BCL2 inhibitor 29 | BGB-21447 inhibits BCL2, potentially resulting in enhanced tumor cell apoptosis (NCI Drug Dictionary). | |
| BGB-43395 | BGB43395|BGB 43395 | CDK4 Inhibitor 18 | BGB-43395 selectively inhibits CDK4, potentially resulting in cell cycle arrest and decreased tumor cell proliferation (NCI Drug Dictionary). | |
| Fulvestrant | Faslodex | ICI 182,780 | Hormone - Anti-estrogens 31 | Faslodex (fulvestrant) is a competitive inhibitor of estrogen that binds and deforms estrogen receptors, and causes inhibition of growth in cultured estrogen-sensitive breast cancer cells and is FDA approved for use in patients with hormone receptor-positive breast cancer (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06756932 | Phase I | BGB-21447 BGB-21447 + BGB-43395 + Fulvestrant BGB-21447 + Fulvestrant | BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer | Recruiting | USA | AUS | 1 |